Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

The Lancet HIV

Volumn 3, Issue 4, 2016, Pages e158-e165

  Gallant, Joel E ^a   Daar, Eric S ^b   Raffi, François ^c   Brinson, Cynthia ^d   Ruane, Peter ^e   DeJesus, Edwin ^f   Johnson, Margaret ^g   Clumeck, Nathan ^h   Osiyemi, Olayemi ⁱ   Ward, Doug ^j   Morales Ramirez, Javier ^k   Yan, Mingjin ^l   Abram, Michael E ^l   Plummer, Andrew ^l   Cheng, Andrew K ^l   Rhee, Martin S ^l  

^a Southwest CARE Center   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c CMIT   (France)

^d Central Texas Clinical Research   (United States)

^e Peter J Ruane MD Inc   (United States)

^f ORLANDO IMMUNOLOGY CENTER   (United States)

^g ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

ⁱ Triple O Medical Services Inc   (United States)

^j Dupont Circle Physicians Group   (United States)

^k Clinical Research Puerto Rico Inc   (Puerto Rico)

^l GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BETA 2 MICROGLOBULIN; CREATININE; DARUNAVIR; EMTRICITABINE; LOPINAVIR; RETINOL BINDING PROTEIN; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; GS-7340; TENOFOVIR;

ADULT; ARTICLE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTROCARDIOGRAPHY; FEMALE; GENE DOSAGE; GENE SEQUENCE; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; EMTRICITABINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TENOFOVIR;

EID: 84960824872     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)00024-2     Document Type: Article

References (20)

1. 1 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, 2015 (accessed Jan 25, 2015).
2. 2 Gilead Sciences. Viread (tenofovir disoproxil fumarate) package insert. http://www.gilead.com/∼/media/files/pdfs/medicines/hiv/viread/viread_pi.pdf?la=en (accessed Nov 1, 2015).
3. 3 McComsey, GA, Kitch, D, Daar, ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203 (2011), 1791–1801.
4. 4 Markowitz, M, Zolopa, A, Squires, K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother 69 (2014), 1362–1369.
5. 5 Ruane, PJ, DeJesus, E, Berger, D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 63 (2013), 449–455.
6. 6 Sax, PE, Wohl, D, Yin, MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385 (2015), 2606–2615.
7. 7 Sax, PE, Zolopa, A, Brar, I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 67 (2014), 52–58.
8. 8 Mills, A, Crofoot, G Jr, McDonald, C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 69 (2015), 439–445.
9. 9 Gallant, JE, Winston, JA, DeJesus, E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22 (2008), 2155–2163.
10. 10 Wohl, DA, Cohen, C, Gallant, JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 65 (2014), e118–e120.
11. 11 Clumeck, N, Molina, JM, Henry, K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 65 (2014), e121–e124.
12. 12 Gallant, JE, Koenig, E, Andrade-Villanueva, JF, et al. Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J Acquir Immune Defic Syndr 69 (2015), 338–340.
13. 13 European AIDS Clinical Society. European Guidelines for treatment of HIV-infected adults in Europe 8.0. http://www.eacsociety.org/files/2015_eacsguidelines_8.0-english_rev-20151221.pdf, 2015 (accessed Jan 25, 2016).
14. 14 Mills, A, Arribas, JR, Andrade-Villanueva, J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16 (2016), 43–52.
15. 15 German, P, Liu, HC, Szwarcberg, J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 61 (2012), 32–40.
16. 16 Ray, AS, Cihlar, T, Robinson, KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50 (2006), 3297–3304.
17. 17 Pozniak A, Arribas J, Gupta SK, et al. Safety of tenofovir alafenamide in renal impairment [Abstract 795]. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23–26, 2015.
18. 18 Wyatt, C, Baeten, JM, Tenofovir alafenamide for HIV infection: is less more?. Lancet 385 (2015), 2559–2560.
19. 19 Tungsiripat, M, Kitch, D, Glesby, MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24 (2010), 1781–1784.
20. 20 Margot N, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C. Integrated analysis of emergent drug resistance through 48 weeks from clinical studies of HIV-1 treatment-naive subjects receiving E/C/F/TAF. XXIV International HIV Drug Resistance Workshop; Seattle, WA, USA; Feb 21–22; 2015. 6.